About us
We serve global pharma & biotech companies as well as CROs to support drug approvals. Our MetaHeps assay is a decision-enabling drug development tool for DILI causality assessmentd in clinical studies and pharmacovigilance.
We use the power of the MetaHeps assay
Our vision and mission
Our vision
Safer drugs for patients by making DILI causality assessments available globally.
Our Mission
With the MetaHeps assay for DILI causality assessments we support you in getting your drug approved.
Our goal with MetaHeps is to support your projects to find the critical evidence that your drug candidate did not cause DILI.
The company
TransHeps is a spin-off the University of Zurich. We offer our expertise to advice how to integrate our MetaHeps technology into the clinical study design, along with standard and novel biomarkers of liver injury, and services in the form of in vitro assays focused on assessing risks of intrinsic DILI and the underlaying mechanisms of liver toxicity.
The leadership team
We are a team of seasoned scientists dedicated to the investigation and understanding of the mechanisms behind DILI, towards stream-lining drug development processes and patient care. TransHeps is the only industrial service provider of the MetaHeps assay.
The MetaHeps Development Plan
MetaHeps was originally developed at the University of Munich / Germany. The collaboration on the technology with the University of Zurich / Switzerland in the TransBioLine consortium led to its acquisition by the University of Zurich. Subsequently TransHeps acquired the exclusive worldwide license for MetaHeps and is now commercializing and further developing the technology to improve liver safety worldwide.
A.Benesic, et al.
Invention and patent
University of Munich /Germany
Prof. Gerbes Labs
Acquisition of IP
by the University of Zurich
Prof. Kullak-Ublick Labs
TransHeps AG
Founded & fully operational, exclusive worldwide license for MetaHeps
2014
2019
2022
2023
2024
TransBioLine
Qualification
Method transfer and further validation
In collaboration with industrial and academic partners
ISTAND
FDA
Qualification effort ongoing
pre-LOI meeting held​